4Desnick RJ, Brady R, BarrangerJ, et al. Fabry disease, an under - recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement tberapy. Ann Intern Med, 2003, 138: 338-346.
5Ortiz A, OliveiraJP, Waldek S, et al. Nephropathy in males and females with Fabry disease: cross - sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant, 2008, 23: 1600-1607.
6Fervenza FC, Torra R, Lager OJ. Fabry disease: an under?recognized cause of proteinuria. Kidney Int, 2008, 73: 1193- 1199.
7Whybra C, Kampmann C, Krummenauer F, et aI. The mainz severity score index: a new instrument for quantifying the Anderson - Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet, 2004, 65: 299-307.
8Fogo AB, Bostad L, Svarstad E, et al. Scoring system for renal pathology in Fabry disease: report of the international study group of Fabry nephropathy (ISGFN). Nephrol Dial Transplant, 2010,25: 2168-2177.
9Hwu WL, Chien YH, Lee NC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later?onset GLA mutation c.936+919G>A (IVS4+ 919G>A). Hum Mutat, 2009, 30: 1397-1405.
